Scarica l'app Stockscreener
12.08
0.85%
-0.1024
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsMarket Growth Summary & Breakout Confirmation Alerts - newser.com
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Trading Recap & Real-Time Chart Pattern Alerts - newser.com
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceEarnings Per Share Trends & Affordable Trading Strategies - earlytimes.in
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthJuly 2025 Highlights & Weekly Breakout Opportunity Watchlist - newser.com
KalVista Pharmaceuticals Completes Convertible Notes Sale - TipRanks
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.2025 Dividend Review & Breakout Confirmation Trade Signals - newser.com
Published on: 2025-09-28 22:29:02 - earlytimes.in
With HAE Drug EKTERLY Off To A Strong Start, Is Now The Time To Keep An Eye On KalVista Stock? - Nasdaq
KalVista prices upsized offering of $125M of 3.250% notes due 2031 - MSN
KalVista to offer $110M in convertible notes; shares down 10% - MSN
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the 20th German Allergy Congress - Business Wire
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Down 6.9%What's Next? - MarketBeat
Ekterly approved as on-demand therapy for HAE in EU, Switzerland - Angioedema News
KalVista Prices Upsized Offering of $125.0 Million of 3.250 Convertible Senior Notes Due 2031 - MarketScreener
KalVista Pharma falls after $125 mln convertible debt sale - TradingView
KalVista Prices Upsized Offering of $125.0 Million of 3.250% Convertible Senior Notes Due 2031 - Business Wire
KalVista Pharmaceuticals Prices $125 Million Notes Offering - MarketScreener
KalVista plans to offer $110 million in convertible notes By Investing.com - Investing.com Canada
KalVista prices $125 million convertible senior notes offering - Investing.com
KalVista prices $125 million convertible senior notes offering By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals stock falls after convertible notes offering By Investing.com - Investing.com Canada
Kalvista Pharmaceuticals announces proposed offering of $110.0 million of convertible senior notes - MarketScreener
KalVista plans to offer $110 million in convertible notes - Investing.com
Kalvista Pharmaceuticals stock falls after convertible notes offering - Investing.com India
KalVista (KALV) Plans $110M Convertible Senior Notes Offering - GuruFocus
KalVista Pharmaceuticals Proposes Private Offering of $110 Million of Convertible Notes; Shares Fall After Hours - MarketScreener
KalVista Pharma falls after announcing $110 mln convertible debt offering - TradingView
KalVista Pharmaceuticals Announces Proposed Offering of $110.0 Million of Convertible Senior Notes - The Joplin Globe
KalVista Pharmaceuticals Experiences Evaluation Revision Amidst Mixed Market Signals - Markets Mojo
Hereditary Angioedema Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
KalVista Pharmaceuticals, Inc. $KALV Shares Purchased by Rhumbline Advisers - Defense World
Hereditary Angioedema Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight - openPR.com
KalVista’s Regulatory Victory Meets Market Skepticism - AD HOC NEWS
KalVista’s Ekterly approved in EU and Switzerland - The Pharma Letter
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY® (sebetralstat), First and Only Oral On-Demand Treatment for Hereditary Angioedema - BioSpace
Decliners Report: What analysts say about KalVista Pharmaceuticals Inc stockJuly 2025 Macro Moves & Scalable Portfolio Growth Methods - خودرو بانک
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Analyzing KalVista Pharmaceuticals Inc. with risk reward ratio charts2025 Investor Takeaways & Daily Price Action Insights - newser.com
Hereditary Angioedema Pipeline Drugs Report 2025 - openPR.com
KalVista Pharmaceuticals’ Hereditary Angioedema Drug Approved In EU, Switzerland: Retail Sees Stock Rallying To $22 In A Year - Stocktwits
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval - Investing.com India
Earnings Miss: Can KalVista Pharmaceuticals Inc. deliver consistent dividendsJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - khodrobank.com
KalVista (KALV) Secures EU Approval for Hereditary Angioedema Tr - GuruFocus
KalVista’s oral HAE treatment Ekterly receives EU and Swiss approval By Investing.com - Investing.com Nigeria
Gold miners, Perpetua Resources, KalVista Pharmaceuticals - TradingView
KalVista (KALV) Gains European and Swiss Approval for Ekterly - GuruFocus
KalVista Pharmaceuticals Announces European Commission and Swissmedic Approval of EKTERLY - Business Wire
1.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):